UK CMA has commenced the merger inquiry into the E.ON (EOAN GY) and OVO Energy deal

Newsquawk StaffPublished On the live feed at 08:054 more headlines followed before this page went public
Newsquawk headlines
06:05

European Equity pre-Market Summary - 2nd September 2026: A slew of bank broker changes and focus on Euro Stoxx 50 reshuffle

05:50

Newsquawk Daily European Equity Opening News - 2nd September 2026

08:05

UK CMA has commenced the merger inquiry into the E.ON (EOAN GY) and OVO Energy deal

08:20

[MARKET ANALYSIS] European bourses lower for a third consecutive day, NOKIA FH and ENGI FP to be added to Euro Stoxx 50

07:05

European Movers: Deutsche Bank (DBK GY) +1.3%, L'Oreal (OR FP) +1.2%, BP (BP/ LN) +1%, Barclays (BARC LN) -0.5%, Ryanair (RYA ID) -2%, GEA (G1A GY) -2.5%

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

A UK Competition and Markets Authority merger inquiry is the standard opening phase of the regulator's review process, and its commencement is procedural rather than a signal on the outcome; the substantive fork comes later, between clearance, clearance with undertakings, and escalation to a deeper phase of investigation. In UK energy retail consolidation, precedent has been mixed: large supplier combinations have cleared with limited remedies, but reviews in concentrated consumer markets have also ended in prohibition or unwinding, so the remedy question rather than the clearance question has tended to be where the economics of the deal are decided. The relevant comparison set is prior big-supplier transactions in the UK retail market, where customer overlap and the share of the combined book in supply metering have been the lines the regulator has tested. For E.ON the exposure is bounded: the target is a retail book within a large, diversified utility, so the equity read has historically been modest unless remedies reach into the scale rationale of the acquisition. Worth watching is whether the inquiry is fast-tracked or referred for an in-depth probe, since that referral decision is the point at which timetable and completion risk actually reprice. As a commencement notice, this is calendar-setting rather than a verdict.

Related headlines